Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Findings from the KEYNOTE-522 study among patients with stage II and III triple-negative breast cancer
Results from the NCI-MATCH ECOG-ACRIN study (EAY131) subprotocol Z1F
Large sex differences were observed among patients who received particularly immunotherapy
Dasatinib Accord and Dasatinib Accordpharma are generic of Sprycel, which has been authorised in the EU since 2006
Updated efficacy and safety data from the CheckMate 743 study
Five-year survival data from the PACIFIC study
Evidence for efficacy is based on the results from the IMCgp100-202 study
It is indicated for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma and follicular lymphoma grade 3B, after two or more lines of systemic therapy
Findings from the IFCT-1703 R2D2 study
Findings from the Consortium of Investigators of Modifiers of BRCA1/2 study
Evidence for efficacy is based on the results from the GVHD-1 and GVHD-2 studies
Findings from updated data analysis in the anaplastic thyroid cancer cohort from the ROAR basket study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
